Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part, Phase I/II, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of the Safety and Efficacy of Topically Applied AMTX-100 CF in Adult Patients With Mild to Moderate Atopic Dermatitis

NCT04313400 is registered in ClinicalTrials.gov with Amytrx Therapeutics, Inc. as lead sponsor.

NCT NCT04313400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04313400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part, Phase I/II, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of the Safety and Efficacy of Topically Applied AMTX-100 CF in Adult Patients With Mild to Moderate Atopic Dermatitis
Lead sponsor
Amytrx Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 10, 2020
Completion date
January 2, 2024
Enrollment
91 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis